Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction

Lorgis, Luc; Cottin, Yves; Danchin, Nicolás; Mock, Laurent; Sicard, Pierre; Buffet, Philippe; L’Huillier, Isabelle; Richard, Carole; Beer, Jean‐Claude; Touzery, Claude; Gambert, Philippe; Zeller, Marianne

doi:10.1136/hrt.2010.213041

Cited by 24 publications

(22 citation statements)

References 29 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar findings were reported when troponin and brain natriuretic peptide were used in addition to the TIMI risk score 19. Their addition produced only a slight increase in the c statistic but, as with NT-proBNP, they were able to identify a subgroup of the TIMI high-risk group who were at very high risk of adverse events, and in whom an aggressive approach to drug therapy and interventions might be warranted 18. Damman and colleagues20 examined a cohort of patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction.…”

Section: Do Biomarkers Add Value?supporting

confidence: 73%

See 1 more Smart Citation

Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

Pell

2012

Heart

View full text Add to dashboard Cite

Section: Do Biomarkers Add Value?supporting

confidence: 73%

“…This was sixfold higher than the referent group. NT-proBNP was found to be a useful addition across all age groups but not in obese patients, in whom NT-proBNP levels were much lower 18. Similar findings were reported when troponin and brain natriuretic peptide were used in addition to the TIMI risk score 19.…”

Section: Do Biomarkers Add Value?supporting

confidence: 71%

Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

Pell

2012

Heart

View full text Add to dashboard Cite

“…Similar findings were reported when troponin and brain natriuretic peptide were used in addition to the TIMI risk score (19). Their addition produced only a slight increase in the c statistic but, as with NT-proBNP, they were able to identify a subgroup of the TIMI high-risk group who were at very high risk of adverse events, and in whom an aggressive approach to drug therapy and interventions might be warranted (18). Damman and colleagues (20) examined a cohort of patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction.…”

Section: Do Biomarkers Add Value?supporting

confidence: 69%

Almanac 2012: cardiovascular risk scores. The journals present selected research that has driven recent advances in clinical cardiology

Pell¹

2013

AnadoluKardiyolDerg

View full text Add to dashboard Cite

Acknowledgement of permission for re-publication: The article was first published in Heart (Pell JP. Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart. 2012 Sep;98(17):1272-7. doi: 10.1136/heartjnl-2012 and is republished with permission. Jill P. PellInstitute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ-UK ABSTRACT Global risk scores use individual level information on non-modifiable risk factors (such as age, sex, ethnicity and family history) and modifiable risk factors (such as smoking status and blood pressure) to predict an individual's absolute risk of an adverse event over a specified period of time in the future. Cardiovascular risk scores have two major uses in practice. First, they can be used to dichotomise people into a group whose baseline risk, and therefore potential absolute benefit, is sufficiently high to justify the costs and risks associated with an intervention (whether treatment or prevention) and a group with a lower absolute risk to whom the intervention is usually denied. Second, they can be used to assess the effectiveness of an intervention (such as smoking cessation or antihypertensive treatment) at reducing an individual's risk of future adverse events. In this context, they can be helpful in informing patients, motivating them to change their lifestyle, and reinforcing the importance of continued compliance.

show abstract

“…Several recent reports suggest that obesity, as indexed by elevated body mass index (BMI), may also affect NT-proBNP levels, with lower circulating levels in those with higher BMI in subjects with acute or chronic heart failure [2], [3], significant coronary artery disease or acute myocardial infarction [4], [5] and healthy general populations [6]. However, isolated study showed that obesity is not statistically associated with NT-proBNP in asymptomatic patients with hypertension [7].…”

Section: Introductionmentioning

confidence: 99%

Impact of Body Mass Index on Plasma N-Terminal ProB-Type Natriuretic Peptides in Chinese Atrial Fibrillation Patients without Heart Failure

Zheng

Yao

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundAn inverse relationship between body mass index (BMI) and circulating levels of N-terminal proB-type natriuretic peptide (NT-proBNP) has been demonstrated in subjects with and without heart failure. Obesity also has been linked with increased incidence of atrial fibrillation (AF), but its influence on NT-proBNP concentrations in AF patients remains unclear. This study aimed to investigate the effect of BMI on NT-proBNP levels in AF patients without heart failure.MethodsA total of 239 consecutive patients with AF undergoing catheter ablation were evaluated. Levels of NT-proBNP and clinical characteristics were compared in overweight or obese (BMI≥25 kg/m2) and normal weight (BMI<25 kg/m2) patients.ResultsOf 239 patients, 129 (54%) were overweight or obese. Overweight or obese patients were younger, more likely to have a history of nonparoxysmal AF, hypertension, and diabetes mellitus. Levels of NT-proBNP were significantly lower in overweight or obese than in normal weight subjects (P<0.05). The relationship of obesity and decreased NT-proBNP levels persisted in subgroup of hypertension, both gender and both age levels (≥65 yrs and <65 yrs).Multivariate linear regression identified BMI as an independent negative correlate of LogNT-proBNP level.ConclusionsAn inverse relationship between BMI and plasma NT-proBNP concentrations have been demonstrated in AF patients without heart failure. Overweight or obese patients with AF appear to have lower NT-proBNP levels than normal weight patients.

show abstract

Impact of obesity on the prognostic value of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with acute myocardial infarction

Abstract: In this large population of patients with myocardial infarction, circulating NT-proBNP levels were considerably lower in obese patients; the significance of the propeptide level as an independent prognostic factor is severely compromised.

Cited by 24 publications

References 29 publications

Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

Almanac 2012: cardiovascular risk scores. The national society journals present selected research that has driven recent advances in clinical cardiology

Almanac 2012: cardiovascular risk scores. The journals present selected research that has driven recent advances in clinical cardiology

Impact of Body Mass Index on Plasma N-Terminal ProB-Type Natriuretic Peptides in Chinese Atrial Fibrillation Patients without Heart Failure

Contact Info

Product

Resources

About